Interactions between cannabidiol and Δ9‐tetrahydrocannabinol in modulating seizure susceptibility and survival in a mouse model of Dravet syndrome. (27th July 2020)
- Record Type:
- Journal Article
- Title:
- Interactions between cannabidiol and Δ9‐tetrahydrocannabinol in modulating seizure susceptibility and survival in a mouse model of Dravet syndrome. (27th July 2020)
- Main Title:
- Interactions between cannabidiol and Δ9‐tetrahydrocannabinol in modulating seizure susceptibility and survival in a mouse model of Dravet syndrome
- Authors:
- Anderson, Lyndsey L.
Low, Ivan K.
McGregor, Iain S.
Arnold, Jonathon C. - Abstract:
- Abstract : Background and Purpose: Extracts from the cannabis plant can dramatically improve the health of children suffering from refractory epilepsies such as Dravet syndrome. These extracts typically contain cannabidiol (CBD), a phytocannabinoid with well‐documented anticonvulsant effects, but may also contain Δ 9 ‐tetrahydrocannabinol (Δ 9 ‐THC). It is unclear whether the presence of Δ 9 ‐THC modulates the anticonvulsant efficacy of CBD. Here, we utilized the Scn1a +/− mouse model of Dravet syndrome to examine this question. Experimental Approach: Scn1a +/− mice recapitulate core features of Dravet syndrome, including hyperthermia‐induced seizures, early onset spontaneous seizures and sudden death. We assessed the effects on CBD and Δ 9 ‐THC alone, and in combination on hyperthermia‐induced seizures, spontaneous seizures and premature mortality. Key Results: Administered alone, CBD (100 mg·kg −1 i.p.) was anticonvulsant against hyperthermia‐induced seizures as were low (0.1 and 0.3 mg·kg −1 i.p.) but not higher doses of Δ 9 ‐THC. A subthreshold dose of CBD (12 mg·kg −1 ) enhanced the anticonvulsant effects of Δ 9 ‐THC (0.1 mg·kg −1 ). Sub‐chronic oral administration of Δ 9 ‐THC or CBD alone did not affect spontaneous seizure frequency or mortality while, surprisingly, their co‐administration increased the severity of spontaneous seizures and overall mortality. Conclusion and Implications: Low doses of Δ 9 ‐THC are anticonvulsant against hyperthermia‐induced seizures inAbstract : Background and Purpose: Extracts from the cannabis plant can dramatically improve the health of children suffering from refractory epilepsies such as Dravet syndrome. These extracts typically contain cannabidiol (CBD), a phytocannabinoid with well‐documented anticonvulsant effects, but may also contain Δ 9 ‐tetrahydrocannabinol (Δ 9 ‐THC). It is unclear whether the presence of Δ 9 ‐THC modulates the anticonvulsant efficacy of CBD. Here, we utilized the Scn1a +/− mouse model of Dravet syndrome to examine this question. Experimental Approach: Scn1a +/− mice recapitulate core features of Dravet syndrome, including hyperthermia‐induced seizures, early onset spontaneous seizures and sudden death. We assessed the effects on CBD and Δ 9 ‐THC alone, and in combination on hyperthermia‐induced seizures, spontaneous seizures and premature mortality. Key Results: Administered alone, CBD (100 mg·kg −1 i.p.) was anticonvulsant against hyperthermia‐induced seizures as were low (0.1 and 0.3 mg·kg −1 i.p.) but not higher doses of Δ 9 ‐THC. A subthreshold dose of CBD (12 mg·kg −1 ) enhanced the anticonvulsant effects of Δ 9 ‐THC (0.1 mg·kg −1 ). Sub‐chronic oral administration of Δ 9 ‐THC or CBD alone did not affect spontaneous seizure frequency or mortality while, surprisingly, their co‐administration increased the severity of spontaneous seizures and overall mortality. Conclusion and Implications: Low doses of Δ 9 ‐THC are anticonvulsant against hyperthermia‐induced seizures in Scn1a +/− mice, effects that are enhanced by a sub‐anticonvulsant dose of CBD. However, proconvulsant effects and increased premature mortality are observed when CBD and Δ 9 ‐THC are sub‐chronically dosed in combination. The possible explanations and implications of this are discussed. … (more)
- Is Part Of:
- British journal of pharmacology. Volume 177:Number 18(2020)
- Journal:
- British journal of pharmacology
- Issue:
- Volume 177:Number 18(2020)
- Issue Display:
- Volume 177, Issue 18 (2020)
- Year:
- 2020
- Volume:
- 177
- Issue:
- 18
- Issue Sort Value:
- 2020-0177-0018-0000
- Page Start:
- 4261
- Page End:
- 4274
- Publication Date:
- 2020-07-27
- Subjects:
- Pharmacology -- Periodicals
Chemotherapy -- Periodicals
Drug Therapy -- Periodicals
Pharmacology -- Periodicals
615.1 - Journal URLs:
- http://bibpurl.oclc.org/web/21844 ↗
http://onlinelibrary.wiley.com/journal/10.1111/(ISSN)1476-5381/issues ↗
http://www.pubmedcentral.nih.gov/tocrender.fcgi?journal=282&action=archive ↗
http://onlinelibrary.wiley.com/ ↗
http://www.nature.com/bjp/index.html ↗ - DOI:
- 10.1111/bph.15181 ↗
- Languages:
- English
- ISSNs:
- 0007-1188
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - 2314.700000
British Library DSC - BLDSS-3PM
British Library STI - ELD Digital store - Ingest File:
- 20890.xml